Beyond CMV Prevention
Beyond CMV Prevention

Released: November 06, 2023

Raymund Razonable
Raymund Razonable, MD

Activity

Progress
1
Course Completed

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:

  • CMV treatment goals
  • CMV treatment and monitoring recommendations
  • Role of secondary prophylaxis
  • Use of CMV cell–mediated immunity (CMI) monitoring for CMV relapse risk
  • Use of CMV CMI for secondary prophylaxis
  • Proposed use of CMV CMI monitoring for secondary prophylaxis
  • Incidence and outcomes with antiviral resistance
  • Risk factors for CMV resistance
  • When to suspect antiviral resistance
  • Testing for antiviral resistance using genotypic assays
  • Outcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virus
  • Treatment recommendations for resistant/refractory CMV
  • Efficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE study
  • Treatment algorithm for resistant/refractory CMV
  • Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV